OptimizeRx Appoints Todd Inman as Chief Technology Officer
02 März 2020 - 2:31PM
OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital
health solutions for pharmaceutical companies, payers, medtech and
medical associations, has appointed Todd Inman as chief technology
officer.
Inman brings to the position more than 30 years of experience
delivering outcomes across the healthcare technology industry.
Since joining OptimizeRx in January 2019 as VP of Technology, he
has led the company’s technology innovation teams in the U.S.,
Europe and Israel. Inman has overseen OptimizeRx’s establishment of
a state-of-the-art AWS cloud backbone, data and analytics
infrastructure, and the recently announced OptimizeRx Innovation
Lab. He will continue leading the implementation and development of
the company’s newly integrated communications platform.
“Todd’s appointment to this new position reflects our commitment
to technology innovation that improves patient-centered care,
access and adherence to medications,” said Miriam Paramore,
president of OptimizeRx. “Given Todd’s expertise and track record
of success, he is uniquely suited to fulfill the role of chief
technology officer. He recently led the successful technology
integration of our newly acquired companies, and we’re looking
forward to many more great things to come.”
Inman commented: “I’m honored to take on this role at OptimizeRx
to continue building and growing a world-class platform that
creates better communication pathways within the healthcare
industry. Leveraging the power of technology to streamline
communication among stakeholders in the care journey is critical,
and I couldn’t be more excited to contribute to that global effort
with the best team in its class.”
Prior to OptimizeRx, Inman has held leadership roles within
prominent health technology and information services companies.
While leading data solutions at a large publicly traded health IT
company, Inman directed the design and implementation of the
company’s big data strategy. This resulted in an AWS cloud-based
data asset of over 30 billion digital health records for 230
million patients. With this highly secured and compliant health
information asset, he led artificial intelligence, machine
learning, and business intelligence efforts that resulted in the
creation of numerous solutions benefiting providers, payers, and
patients.
Inman and other OptimizeRx leaders will be attending HIMSS in
Orlando on March 9-13, 2020, to demonstrate the industry-leading
technology connecting provider and patient communications from the
point-of-care and beyond. To schedule a meeting, please email
malejandra@optimizerx.com.
About OptimizeRxOptimizeRx® (NASDAQ: OPRX), a
digital health company, connects pharmaceutical companies to
patients and providers, offering greater affordability, adherence
and brand awareness at the point-of-care. As the nation’s largest
digital platform connecting life sciences to the point-of-care,
OptimizeRx provides a direct channel for payers, medtech companies,
medical associations and pharma companies to communicate with
healthcare providers right within their workflow and also directly
to patients.
The cloud-based solution supports patient adherence to
medications and better healthcare outcomes with real-time access to
financial assistance, prior authorization, education and critical
clinical information. OptimizeRx provides more than half of the
ambulatory patient market with access to these benefits through
leading EHR platforms like Allscripts, Amazing Charts and Quest,
and directly via its mobile communications platform and digital
therapeutics SaaS platform.
For more information, follow the company on Twitter, LinkedIn or
visit www.OptimizeRx.com.
Important Cautions Regarding Forward Looking
StatementsThis press release contains forward-looking
statements within the definition of Section 27A of the Securities
Act of 1933, as amended, and such as in section 21E of the
Securities Act of 1934, as amended. These forward-looking
statements should not be used to make an investment decision. The
words 'estimate,' 'possible' and 'seeking' and similar expressions
identify forward-looking statements, which speak only as to the
date the statement was made. The company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted, or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition and other material
risks.
OptimizeRx Contact Doug
Baker, CFO Tel (248) 651-6568
x807 dbaker@optimizerx.com
Media Relations Contact Maira Alejandra,
Media Relations ManagerTel (754) 245-7070
investors@optimizerx.com
Investor Relations Contact Ron Both,
CMA Tel (949) 432-7557 oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024